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Abstract 
Stressful conditions in the harsh tumor microenvironment induce autophagy in 
cancer cells as a mechanism to promote their survival. However, autophagy also 
causes post-translational modification of proteins which are recognized by the 
immune system. In particular, modified self-antigens can trigger CD4+ T cell 
responses that might be exploited to boost antitumor immune defenses. In this study, 
we investigated the ability of CD4 cells to target tumor-specific self-antigens modified 
by citrullination, which converts arginine residues in proteins to citrulline. Focusing 
on the intermediate filament protein vimentin, which is frequently citrullinated in cells 
during epithelial-to-mesenchymal transition of metastasizing epithelial tumors, we 
generated citrullinated vimentin peptides for immunization experiments in mice. 
Immunization with these peptides induced IFNγ- and granzyme B-secreting CD4 T 
cells in response to autophagic tumor targets. Remarkably, a single 
immunization with modified peptide, up to 14 days after tumor implant, resulted in 
long term survival in 60-90% of animals with no associated toxicity. This antitumor 
response was dependent on CD4 cells and not CD8+ T cells. These results show 
how CD4 cells can mediate potent antitumor responses against modified self-
epitopes presented on tumor cells, and they illustrate for the first time how the 
citrullinated peptides may offer especially attractive vaccine targets for cancer 
therapy. 
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Introduction 
One of the limitations of tumor immunotherapy is the immunosuppressive tumor 
environment. This can be partly abrogated by removing regulatory T cells (Tregs), 
inhibiting myeloid suppressor cells, neutralizing PD-L1 (1) or enhancing T cell 
responsiveness using checkpoint inhibitors targeting CTLA-4 and PD-1 (2-5).  The 
checkpoint inhibitors have had a dramatic effect on survival in melanoma patients 
but are associated with 10-53% grade 3/4 autoimmune complications (2, 3, 5). CD4 
T cells are the orchestrators of the immune response and, when activated within a 
tumour, release interferons (IFNs) that act directly to upregulate MHC and stimulate 
the release of pro-inflammatory chemokines to promote further immune infiltration (6-
8). The CD4 repertoire to self-antigens is highly tolerised (9-11). In contrast, CD4 T 
cells recognizing modified self-epitopes have been shown to play a role in the 
pathophysiology of several autoimmune diseases such as rheumatoid arthritis (RA), 
collagen II-induced arthritis, sarcoidosis, celiac disease and psoriasis (12-15). One of 
these common modifications is citrullination of arginine which involves the 
conversion of the positively charge aldimine group (=NH) group of arginine to the 
neutrally charged ketone group (=O) of citrulline. Citrullination is mediated by 
Peptidylarginine deiminases (PADs), which are a family of calcium dependent 
enzymes found in a variety of tissues. A recent elegant report by Ireland et al. 
demonstrates that the presentation of citrullinated T cell epitopes on APCs is also 
dependent upon autophagy and PAD activity (16). This process has also been 
demonstrated to be an efficient mechanism to enable processing of endogenous 
antigens for presentation on MHC class II molecules in professional APCs as well as 
epithelial cells (17, 18). It has also been demonstrated that induction of autophagy 
increases the presentation of cytosolic proteins in B cells and thymic epithelial cells 
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(19, 20).   Autophagy is constitutive in APCs but is only induced by stress in other 
cells (21). Thus T cells recognizing citrullinated epitopes have no target on normal 
healthy cells. Autophagy is triggered by stress such as hypoxia and nutrient 
starvation and is upregulated to promote tumor survival (21). One of the most 
frequently citrullinated proteins is vimentin, a cytoskeletal protein expressed by all 
mesenchymal cells and one of the first proteins to be upregulated during epithelial to 
mesenchymal transition of metastasizing epithelial tumors.  In addition, it has also 
recently been shown to be citrullinated in some human tumor cell lines (22).  
 
In this study we show that it is possible to induce CD4 responses to citrullinated self-
peptide epitopes with minimal reactivity to the unmodified sequence.  We are the first 
to demonstrate that tumor cells present citrullinated epitopes.  T cells specific for 
these citrullinated peptide epitopes can target tumor cells to elicit strong anti-tumor 
effects in vivo, thus providing the first evidence for the use of citrullinated peptides as 
vaccine targets in cancer therapy. 
 
Materials and Methods 
Cell lines and culture 
The T cell/B cell hybrid cell line T2 stably transfected with functional class II DR4 
(DRB1*0401; T2 DR4) has been described (23). Murine pancreatic cancer cell line 
Pan02 was obtained from the DCTD Tumor/Cell line repository at National Cancer 
Institute, USA. The murine melanoma B16F1 cell line and murine lung carcinoma 
line LLC/2 were obtained from the ATCC.  All cell lines were cultured in RPMI 
medium 1640 (GIBCO/BRL) supplemented with 10% FCS, L-glutamine (2 mM) and 
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sodium bicarbonate buffered. Cell lines utilized are mycoplasma free, authenticated 
by suppliers (STR profiling) and used within ten passages.   
To stress tumor target cells for in vitro assays, cells were treated with 0.1M citric acid 
(pH3.0) containing 1% BSA at 4 ˚C for 2 minutes, washed with media and cultured in 
absence of serum for 20 hours at 37 ˚C. Autophagy and PAD inhibitors, 3-
methyladenine (Sigma) and CI-amidine (Calbiochem), at final concentrations of 10 
mM and 50 µg/ml respectively or rapamycin (Calbiochem) and bafilomycin 
(Calbiochem) at final concentrations of 800 nmol and 500 nmol respectively were 
added for the 20 hr culture in serum free media.   
 
Peptides 
Peptides aa14-32cit (MFGGSGTSS-cit-PSSN-cit-SYVT), aa26-44cit (SN-cit-
SYVTTST-cit-TYSLGSAL), aa28-49wt (RSYVTTSTRTYSLGSALRPSTS), aa28-49cit 
(cit-SYVTTST-cit-TYSLGSAL-cit-PSTS), aa31-50cit (VTTST-cit-TYSLGSAL-cit-
PSTS-cit), aa36-54cit (cit-TYSLGSAL-cit-PSTS-cit-SLYS), aa46-64cit (PSTS-cit-
SLYSSSPGGAYVT-cit-S), aa401-419cit (cit-KLLEGEES-cit-ISLPLPTFS), aa406-
425cit (GEES-cit-ISLPLPTFSSLNL-cit-E), aa415-433wt 
(LPNFSSLNLRETNLDSLPL) and aa415-433cit (LPNFSSLNL-cit-ETNLDSLPL) were 
synthesized at > 90% purity by Genscript (USA) and stored lyophilized at -80 °C. On 
the day of use they were reconstituted to the appropriate concentration in 10% 
dimethyl formamide. 
 
Plasmids 
To construct the plasmid pVitro 2 Chimeric HLA-DR401, cDNA was generated from 
mRNA isolated from the splenocytes of transgenic HLA-DR4 mice. This was used to 
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amplify the chimeric alpha and beta chains separately using forward and reverse 
primers that incorporated a FspI/EcoRI and BamHI/SalI sites respectively. Following 
sequence confirmation full length chimeric alpha chain comprising murine H2-Ea 
with the human HLA-DRA alpha 1 domain was ligated into the FspI/EcoRI mcs2 of 
the vector pVITRO2-hygro-mcs (Invivogen). The beta chain comprising murine H2-
Eb with human DRB1*0401 Beta 1 domain was then inserted into the BamHI/SalI 
mcs1 of the vector alongside the chimeric alpha chain.  
To generate the IFNγ inducible plasmid pDCGAS chimeric HLA-DR401, the chimeric 
alpha and beta chains, were cloned into the pDCOrig vector described elsewhere 
(24) in replacement of the heavy and light chain. The IFNγ inducible promoter 
consisting of a TATA box and the GAS (IFNγ activated sequence) direct repeat 
enhancer element was amplified by PCR utilizing the vector pGAS-Luc (Agilent) as a 
template. The CMV promoter within each cassette was excised and replaced with 
the IFNγ inducible promoter driving expression of the HLA-DR401 chains within the 
pDCOrig vector backbone. 
The plasmid MC207329 (Origene) encoding untagged full length murine Myelin 
Oligodendrocyte Glycoprotein cDNA (NM_010814) was cloned into the SgfI/MluI 
mcs of the mammalian expression vector pCMV 6. 
After sequence confirmation endotoxin free plasmid DNA was generated using the 
endofree maxiprep kit (Qiagen). 
 
Transfection and flow cytometry 
B16F1 melanoma, LLC/2 lung carcinoma, and Pan02 pancreatic cancer cells were 
transfected using the lipofectamine transfection reagent (Invitrogen) with 4 µg of the 
plasmid pVitro 2 Chimeric HLA-DR401 that encodes both full length chimeric alpha 
8 
 
and beta chains according to the manufacturer’s instructions. The B16F1 cell line 
was transfected with either the MOG plasmid or the pDC GAS chimeric HLA-DR401 
or the pVitro 2 chimeric HLA-DR401 plasmids where chimeric HLA-DR401 is under 
expression of the IFNγ inducible promoter or the constitutive promoter that drive high 
level expression respectively. 
 Transfected cells were selected by growth in the presence of G418 (500μg/ml), 
zeocin (300 µg/ml) or hygromycin B (300 µg/ml). Lines were cloned by limiting 
dilution and expression was confirmed by flow cytometry using the HLA-DR PE 
conjugated antibody (clone L243) from eBioscience or the murine MOG antibody 
(clone 8-18C5, Millipore) with the anti-mouse IgG1 AlexaFluor 647 secondary 
antibody (Life Technologies). Cells transfected with the IFNγ inducible plasmid 
where incubated overnight in the absence or presence of murine IFNγ (30 ng/ml, 
Gibco life technologies) prior to staining with the antibody. 
 
HLADR*0401 binding studies 
In brief, peptides of interest were mixed with a predetermined concentration of 
biotinylated influenza haemagglutinin HA 306-318 reference peptide at increasing 
concentrations and added to plate bound HLA-DR*0401.  The amount of biotinylated 
reference peptide binding to HLA DR*0401 was quantified using a streptavidin-linked 
enzyme step followed by detection with chromogenic substrate.  Maximal binding is 
taken as the value achieved by biotinylated HA 306-318 peptide alone.  As a positive 
control unlabeled HA 306-318 peptide was used to compete with the biotinylated 
version. 
 
Immunization protocol 
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HLA-DR4 mice (Model # 4149, Taconic) or C57Bl/6J mice (Charles River, UK) aged 
between 8 and 12 weeks were used. All work was carried out at Nottingham Trent 
University under a Home Office approved project license. For all studies the mice 
were randomized into different groups and not blinded to the investigators. Peptides 
were dissolved in 10% dimethylformamide to 1 mg/ml and then emulsified with CpG 
and MPLA 6 µg/mouse of each (Invivogen).  Peptides (25 µg/mouse) were injected 
subcutaneously at the base of the tail. Mice were immunized on day 0 and spleens 
were removed for analysis at day 12. Antibodies to IFNγ (clone XMG1.2), IL-17 
(clone 17F3), CD8 (clone 2.43) and CD4 (clone GK1.5) were purchased from 
BioXcell.  
For tumor challenge experiments mice were challenged with 2.5x104 B16 DR4 cells, 
1x105 B16 MOG cells or 1.5x106 LLC/2 DR4 cells subcutaneously on the right flank 3 
days prior to primary immunization (unless stated otherwise) and then were 
immunized as above.  The antibodies to IFNγ (300 µg/dose) and IL-17 (200 µg/dose) 
were administered via the intraperitoneal (i.p.) route in saline at days 2, 7, 10 and 14 
post tumor implant.  The CD4 specific antibody (500 µg/dose) was administered i.p. 
in saline at days 2 and 8 post tumor implant.  Tumor growth was monitored at 3-4 
days intervals and mice were humanely euthanized once tumor reached ≥10 mm in 
diameter.   
 
Ex vivo Elispot assay 
Elispot assays were performed using murine IFNγ or IL-17 capture and detection 
reagents according to the manufacturer’s instructions (Mabtech).  In brief, the IFNγ 
or IL-17 specific antibodies were coated onto wells of 96-well Immobilin-P plate.  
Synthetic peptides (10 µg/ml) and 5x105 per well splenocytes were added to the 
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wells of the plate in triplicate.  Tumor target cells were added where relevant at 
5x104/well in triplicate and plates incubated for 40 hrs at 37˚C.  After incubation, 
captured IFNγ or IL-17 were detected by biotinylated specific IFNγ or IL-17 
antibodies and developed with a streptavidin alkaline phosphatase and chromogenic 
substrate.  Spots were analyzed and counted using an automated plate reader 
(Cellular Technologies Ltd). 
 
Ex vivo depletion of CD4 or CD8 cells from splenocyte cultures 
Splenocytes were subject to positive isolation of CD4 or CD8 cells using antibody 
coated magnetic beads (Miltenyi Biotech) according to manufacturer’s instructions.  
For MHC blocking studies 20 µg/ml of the HLA-DR (clone L243) specific antibody 
was added to Elispot assays. 
 
Granzyme B Elisa 
Supernatant from ex vivo IFNγ Elispot assays on splenocytes was removed after 40 
hrs and assessed for Granzyme B by Elisa assay (R&D systems) according to 
manufacturer’s instructions. 
 
Western Blotting  
Cell lines were cultured under different conditions as detailed above with the 
inclusion of E64d and pepstatin A protease inhibitors (10 µg/ml, Calbiochem).  Cell 
lysates were prepared in RIPA buffer containing protease inhibitor cocktail (Sigma) 
and proteins separated on a 12% NuPage Bis-Tris gel (Invitrogen) followed by 
transfer onto PVDF membrane. The membrane was probed with antibodies to 
human/mouse LC3A/B (clone D3U4C, Cell signalling) and β actin (clone AC-15, 
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Sigma).  Proteins were visualized using fluorescent secondary antibodies against 
mouse (for LC3A/B) or rabbit (for β actin) and a Licor detection system.  
Quantification was performed using Image Studio software and the intensity of 
respective bands were normalized to β-actin loading control. 
 
P62 Elisa 
Cell lines were cultured under different conditions as detailed above Lysates were 
prepared in RIPA buffer with PMSF, DNase and protease inhibitor cocktail 
(Calbiochem) and analyzed by p62 Elisa according to manufacturer’s instructions 
(Enzo Life Sciences). 
 
Proliferation assays on human PBMCs 
PBMCs were isolated from normal donors and melanoma patients (ranging from 
early to advanced disease classification) and subject to CFSE labeling (where 
specified).  Cells were cultured with 10 μg/ml peptide and analyzed at day 11 dilution 
of CFSE by flow cytometry combined with staining for CD4 PE-Cy5 (clone RPA-T4, 
eBioscience) and CD8 efluor 450 (clone RPA-T8, eBioscience) or for 3H thymidine 
uptake. 
 
Statistical analysis 
Comparative analysis of the Elispot results was performed by applying unpaired 
Student t test with values of P calculated accordingly.  Comparison of tumor survival 
was assessed by Log Rank test using the Graphpad Prism software. P < 0.05 values 
were considered statistically significant and P < 0.05 values were considered highly 
significant.  The error bars shown in the figures represent the mean + s.d. 
12 
 
 
Results 
Peptide vaccination induces high frequency CD4 responses to two 
citrullinated vimentin epitopes in HLA-DR4 transgenic mice 
Two citrullinated peptide epitopes from vimentin (aa28-49 and aa415-433) were 
selected for this study as they had been previously shown to induce T cell responses 
in mice and humans (25).  The vimentin aa 26-44 peptide from this published study 
was changed to encompass aa 28-49 which allowed inclusion of a third citrulline 
residue and was shown to induce a stronger immune response compared to the 
same peptides containing only two citrulline residues (Supplementary Fig. S1). This 
aa28-49 peptide is completely homologous in mice and humans. To confirm HLA-
DR4 binding the wild type and citrullinated aa28-49 and human aa415-433 peptides 
were screened in HLA-DR4 binding competition assays with influenza 
haemagglutinin HA306-318 peptide.  Vimentin aa28-49 citrullinated peptide shows 
stronger binding to HLA-DR*0401 compared to the wild type version whereas 
citrullinated aa415-433 peptide showed weaker binding (Fig. 1A). 
 
HLA-DR4 transgenic mice were immunized with citrullinated aa28-49 or aa415-433 
peptides in combination with CpG and MPLA adjuvants.  Citrullinated aa28-49 and 
aa415-433 peptides stimulated strong IFNγ responses against the citrullinated 
peptides and no significant responses to the wild type peptide compared to control 
(Fig. 1B and 1Ci). Citrullinated aa415-433 also stimulated strong IL-17 responses 
against the citrullinated peptide and no significant responses to the wild type peptide 
(Fig. 1Cii).  No significant IL-10 responses were observed specific for either the 
aa415-433 or aa28-49 peptides (data not shown).  Since the aa415-433 epitope has 
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two amino acid differences between human and murine sequences, cross reactivity 
to the murine sequence was tested.  Responses induced with the human sequence 
cross reacted with the murine peptide with no wild type reactivity (Fig. 1Ci).  Mice 
also made similar responses if immunized with the murine aa415-433 peptide 
(Supplementary Fig. S2).   
 
Citrullinated epitope specific responses are CD4 mediated and possess 
cytotoxic capability 
Responses specific for citrullinated aa415-433 and aa28-49 peptides were shown to 
be CD4 mediated by depletion of CD4 cells prior to analysis or addition of MHC class 
II blocking antibody (Fig. 2A and B). Depletion of CD8 cells had no effect upon the 
peptide specific responses (Supplementary Fig. S3).  Absence of CD8 epitopes 
within the sequences was confirmed by immunization of C57Bl/6 and HHDII/DR1 
mice. They failed to raise a response suggesting that the epitopes are not presented 
on H-2Kb, H-2Db, I-Ab, HLA-A2 or HLA–DR*0101 (data not shown). 
To assess if citrullinated peptide specific CD4 responses were capable of cytotoxicity 
as well as cytokine release, the secretion of granzyme B was analyzed.  Splenocytes 
from mice immunized with either citrullinated aa28-49 or aa415-433 peptides or both 
demonstrate release of granzyme B, a marker of cytotoxicity, upon stimulation with 
aa415-433 (P<0.0001) and aa28-49 (P<0.0001) citrullinated peptides in contrast to 
the wild type versions (Fig. 2C). 
 
Tumor cells present citrullinated epitopes via autophagy and PAD dependent 
mechanisms  
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The ability of the citrullinated epitope specific responses to recognize tumors was 
assessed. T cells stimulated with the combination of peptides failed to recognize 
targets that expressed HLA-DR4 under normal conditions. However, if the cells were 
stressed by serum starvation good recognition of the mouse cells lines and the 
human T2 DR4 cell line was seen, suggesting that all these cell lines present the 
citrullinated epitope when stressed (Fig. 3A). Granzyme B is also released upon 
response to serum starved B16DR4 tumor target cells suggesting CD4 killing of 
tumor targets presenting the citrullinated epitopes (Fig. 3B). 
 
Since it has been suggested that proteins can undergo citrullination via PAD activity 
in autophagic vesicles, we considered whether autophagy was being induced in the 
cell lines as a result of the stress imposed by serum starvation. The T cell 
recognition assay was repeated and induction of autophagy assessed in the 
presence of inducers or inhibitors of autophagy and inhibitors of PAD.  Immunoblot 
analysis of B16DR4 lysates from cells treated with the autophagy inducer rapamycin 
results in higher levels of expression of the autophagy marker LC3ii indicating an 
increase in autophagic vesicles (Fig. 3Ci).  The inclusion of bafilomycin, which 
prevents autophagosome fusion with lysosomes thus inhibiting protein degradation, 
in the presence of serum starvation increased LC3ii expression compared to 
untreated cells indicating accumulation of autophagosomes in the serum starved 
cells (Fig. 3Ci). The polyubiquitin-binding protein p62/SQSTM1 is known to bind to 
LC3, it is degraded by autophagy and is commonly used alongside LC3 as an 
indicator of autophagy.  The induction of autophagy by serum starvation or 
rapamycin treatment is observed with reduction in levels of p62 which is increased 
on addition of bafilomycin (Fig. 3Cii). T cell recognition of tumor target cells  was 
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increased in the presence of rapamycin and blocked on serum starvation in the 
presence of bafilomycin and the autophagy inhibitor 3-methyladenine (3-MA).  T cell 
recognition of serum starved tumor cells was also decreased in the presence of PAD 
inhibitor CI-amidine indicating that the presentation and T cell recognition of 
citrullinated peptides is both autophagy and PAD dependent (Fig. 3D).    
 
Citrullinated vimentin specific CD4 responses show anti-tumor activity in vivo 
against established tumors 
To assess the anti-tumor activity in vivo, HLA-DR4 transgenic mice were implanted 
with B16F1 tumors expressing HLA-DR4 followed byimmunization with single or 
combination of citrullinated peptides.  Mice immunized with citrullinated peptides 
demonstrate strong anti-tumor responses (Fig. 4A). 
To test if the immune responses were as efficient against more established tumors, 
vaccination was delayed until 7, 10 or 14 days post B16 tumor implant.  A single 
vaccination with both peptides shows enhanced survival in mice even when 
vaccination is delayed until day 14 post tumor implant (Fig. 4B and C) or if tumor is 
initiated with 6 fold higher tumor load (Fig. 4D). 
 
Anti-tumor responses induced by each peptide are CD4 mediated and IFNγ 
dependent 
To determine if these anti-tumor responses were mediated by CD4 T cells, mice 
were treated with anti-CD4 antibody in vivo.  Vaccination combined with CD4 T cell 
depletion totally abrogates the anti-tumor response mediated by both peptides (Fig. 
5A).  The influence of CD8 cells on the anti-tumor effect was assessed by use of 
anti-CD8 antibody combined with vaccination.  Depletion of CD8 cells had no 
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significant effect upon the anti-tumor effect (Fig. 5B).  Both citrullinated peptides 
induce high frequency IFNγ responses.  Blockade of IFNγ in vivo inhibits both 
citrullinated peptide specific anti-tumor responses (Fig. 5C). Citrullinated aa415-433 
also induces IL-17 responses.  Blockade of these in vivo had a weak, but significant, 
influence upon in vivo anti-tumor effects (Fig. 5D).   
 
Do the anti-tumor responses require HLA-DR4 expression by the tumor 
CD4 responses within tumor sites can be stimulated by APCs presenting tumor 
antigens. This can trigger the release of cytokines and chemokines promoting 
inflammation and recruitment of other effector cells. Alternatively, CD4 T cells can 
differentiate to cytotoxic cells expressing granzyme and Fas Ligand and directly kill 
tumors expressing MHC-II. As the anti-tumor responses of the citrullinated peptides 
were not dependent upon CD8 T cells this suggested that direct recognition of 
tumors by the CD4 T cells was important. To address this issue HLA-DR4 transgenic 
mice were implanted with B16F1 tumors that do not express HLA-DR4 followed by  
immunization with the combination of citrullinated peptides.  Mice immunized with 
citrullinated peptides showed a weak anti-tumor which failed to show significance 
(Fig. 6A) suggesting direct recognition of HLA-DR4 on tumor cells was important for 
the anti-tumor response. Although, some melanomas constitutively express MHC-II, 
most only express MHCII following IFNγ stimulation. B16F1 were therefore 
transfected with HLA-DR4 under control of the mouse IFNγ inducible promoter GAS. 
IFNγ upregulation of HLA-DR4 was demonstrated on this tumor cell line (Fig. 6Bii). 
HLA-DR4 transgenic mice were implanted with IFNγ inducible HLA-DR4 B16F1 
tumors and immunized with the combination of citrullinated peptides.  Mice 
immunized with citrullinated peptides show a strong anti-tumor response (Fig. 6C) 
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suggesting that the CD4 T cells secreted sufficient IFNγ to induce HLA-DR4 
expression which was important for the anti-tumor response. To show that IFNγ 
alone was not sufficient to induce an anti-tumor response, the mouse lewis lung 
carcinoma LLC/2 which is unresponsive to IFNγ was transfected with HLA-DR4. 
Mice immunized with the combination of citrullinated peptides showed a significant 
anti-tumor response (P=0.0408, Fig. 6D) again suggesting that direct recognition of 
HLA-DR4 on tumor cells was important for the anti-tumor response. 
 
Does citrullinated vimentin represent a novel class of tumor associated 
antigen? 
To demonstrate that citrullinated vimentin represents a tumor associated antigen to 
which T cell have not been tolerised, it was necessary to show responses in wild 
type mice and in human PBMCs in vitro. Myelin oligodendrocyte glycoprotein 
(MOG) aa35-55 is a known citrullinated epitope in C57Bl mice. It contains two 
arginines at positions 41 and 46 that when changed to citrulline induce immune 
responses (26).  The epitope with citrulline at position 46 is known to show lower 
cross reactivity with the wild type sequence and thus minimize autoimmune effects.  
We immunized mice with this peptide and showed strong T cell responses specific 
to the citrullinated peptide (Fig. 7A). MOG was transfected into our B16- tumor 
model and 4 days following tumor implant, mice were immunized with the MOG 35-
55(cit46) citrullinated peptide. Strong anti-tumor responses were induced in 70% of 
mice (Fig. 7B). These results demonstrate that tumors can citrullinate proteins in 
wild type mice. To determine if wild type mice could also respond to citrullinated 
vimentin C57Bl mice were immunized with pools of citrullinated vimentin peptides 
encompassing all regions containing an arginine as published in Fietsma et al. but 
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no responses were observed. Vimentin was further analyzed for I-Ab motifs that 
encompassed an arginine. Six citrullinated peptides were synthesized and used to 
screen C57Bl mice. Two of these showed strong citrulline specific T cell responses 
(Fig. 7C).  Interestingly the strongest response is to sequence aa31-50 which cross 
reacts with the peptide encoding sequence aa26-44.  Both of these contain part of 
the aa28-49 sequence.  It appears that it is the citrulline at position 36 that is 
important in this response (Supplementary Table S1).  We have demonstrated in 
DR4 mice that this region is naturally citrullinated. Another response to the 
citrullinated peptide spanning aa401-419 was detected in C57Bl/6 mice.  This 
response did not cross react with aa406-425 sequence or aa415-433 sequence.  
This data demonstrates that responses to citrullinated epitopes have not been 
deleted in wild type mice and confirms that our responses in the HLA-DR4 
transgenic mice are not an artifact of the transgenic model. Furthermore, melanoma 
patients were screened with the citrullinated peptides aa415-433 and aa28-49. 8/23 
responded to aa415-433 peptide, 8/23 to aa28-49 peptide and 5 patients to both 
epitopes (Fig. 7D). Six of the eight patients showing a proliferative response to 
citrullinated aa415-433 peptide were analyzed for cytokine release (Supplementary 
Table S2). All patients released IFNγ, 3/6 released IL-17, 2/6 TNFα, 2/6 Il-4, 2/6 Il-
10 and 1/6 IL-2. Four of the six patients released at least 3 cytokines and 5/6 two 
cytokines. A normal donor also showed a strong proliferative response which was 
CD4 mediated and specific to the citrullinated peptide (Fig. 7E).  Analysis of the 
HLA restriction of responding patients showed that only one was HLA-DR4 
suggesting these responses were not solely HLA-DR4 mediated and these peptides 
induce responses through a number of HLA-alleles.   
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Discussion 
We provide the first evidence that citrullinated peptides can stimulate potent anti-
tumor responses suggesting that tumor cells present citrullinated peptides on MHC-II 
molecules. Furthermore, this presentation is autophagy and PAD dependent, 
although formal proof of the latter will require PAD knock out cell lines rather than 
just PAD inhibitors. Autophagy is triggered by stress such as hypoxia and nutrient 
starvation and is upregulated to promote tumor survival (21). PAD2 and PAD4 
enzymes have also been shown to be expressed in a variety of cancer types and 
evidence of citrullinated proteins has been demonstrated in some cancer cell lines 
(22, 27, 28). We have shown that the efficient presentation of citrullinated peptides 
from vimentin onto MHC class II molecules is dependent upon autophagy suggesting 
an important role for this process in presentation of modified peptide epitopes in 
tumor cells. The presentation of citrullinated peptides make excellent tumor targets 
resulting in efficient CD4 mediated tumor clearance in melanoma and lung cancer 
models. The citrullinated vimentin specific Th1 response was capable of tumor 
rejection even against  established tumors and high tumor burden.  Immunized mice 
demonstrating strong tumor rejection showed no evidence of toxicity suggesting 
healthy cells do not present these modified epitopes. Indeed, it has been shown that 
RA cannot be induced by T cells alone but requires joint erosion, antibody responses 
and inflammation.  This is borne out by studies where no autoimmune symptoms 
were observed with T cells alone, even in HLA-DR4 transgenic mice which are 
susceptible to RA (29). However, the disease may be exacerbated in patients who 
already have RA and they will be excluded from any clinical studies. Potentially any 
cell undergoing autophagy could present citrullinated vimentin and be a target, 
however, we see no toxicity in the mouse models. We have shown that EBV 
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transformed targets are recognized by splenocytes from immunized mice but this is 
perhaps not surprising as there is a degree of viral replication and cell lysis in these 
lines inducing some cellular stress. We speculate that any virally infected cell may 
also be a target but this should be beneficial rather than toxic. We do believe that 
chemotherapy may stress normal cells and the vaccine would need to be applied 
after recovery from the toxic effects of this therapy. 
 
Frequent recognition of neo-epitopes by CD4 T cells in human melanoma has been 
observed (30). Indeed a recent analysis of responses to neo-epitopes within the 
B16 tumor showed the anti-tumor response to a CD4 neo-epitope was stronger than 
responses to CD8 neo-epitopes (31). In contrast to neo-epitopes, high affinity T 
cells to self-antigens may be deleted. Recent studies using adoptively transferred 
TCR transgenic T cells highlight the important role of CD4 T cells in the direct 
targeting of tumors (32, 33).  These studies relied on the use of TCR transgenic T 
cells as tolerance to the tumor antigen could not be overcome by vaccination.  In 
contrast, we have observed robust CD4 responses to vaccination with citrullinated 
peptides that resulted in anti-tumor immunity. Unlike neo-epitopes, this would not be 
patient specific and could be used to treat a wide range of cancers. The anti-tumor 
response induced by the citrullinated peptides was IFNγ and CD4 dependent, CD8 
independent and required direct recognition of HLA-DR4 on tumors. Although most 
tumors do not express MHC-II constitutively, they can be induced to express high 
levels by IFNγ. We have therefore produced a mouse tumor model that only 
upregulates HLA-DR4 in response to IFNγ. We see strong anti-tumor responses in 
this model. Our results compare favorably with responses to the Kif18b CD4 neo-
epitope expressed within B16 tumors (31). Kreiter et al, showed 60% survival after 8 
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immunizations with an RNA vaccine, commencing one day after tumor initiation. 
They show no anti-tumor response against established tumor when using a peptide 
vaccine encoding this epitope (34). We show 80% survival after a single 
immunization with a citrullinated peptide on day 10 after tumor initiation. 
 
Of particular interest was the secretion of granzyme B in response to the 
citrullinated peptides and tumor cells expressing MHC class II.  This recognition was 
inhibited by molecules which block both autophagy and citrullination. This 
suggested that the vaccination was inducing cytotoxic CD4 T cells.  Cytotoxic CD4s 
have been difficult to induce by vaccination but adoptively transferred naïve CD4s 
recognizing self-antigens have been shown to differentiate to cytotoxic CTL (33) 
and this can be enhanced with OX40 engagement or following CD137/CD134 
costimulation (35, 36). The citrullinated vimentin epitopes in this study induce 
secretion of IL-17 and there is some evidence to suggest Th17 cells can also 
mediate tumor therapy; however the effect mediated by these Th17 cells was also 
shown to be dependent upon IFNγ (37).  Neutralization of IL-17 in this study had 
minimal effects upon the anti-tumor response in vivo and there remains conflict on 
the relevance of Th17s in anti-tumor immunity (38).  It is possible that these 
contradictory results could be due to the plasticity of Th17 cells in vivo (37, 39). 
 
This study provides the first evidence that tumors can present citrullinated peptides 
as targets for CD4 cells. This presentation is dependent upon autophagy and PAD 
enzymes. The CD4 T cells release IFNγ and show direct cytotoxicity which results in 
potent anti-tumor responses in vivo.    This approach is being fast tracked into the 
clinic in patient’s whose tumors express vimentin. This could be patients with 
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mesenchymal tumors or in patients whose tumors undergo epithelial to 
mesenchymal transition as vimentin is one of the first proteins to be expressed in this 
transition 
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Figure Legends 
Figure 1.  Citrullinated peptides induce IFNγ and IL-17 responses.  A, HLA binding 
affinity of citrullinated (cit) and wild type (wt) vimentin peptides.  HLA-DR4 transgenic 
mice were immunized with citrullinated vimentin aa28-49 (B) or aa415-433 (C) 
peptides and splenocytes analyzed for peptide specific IFNγ or IL-17 responses to 
the citrullinated or wild type peptides in Elispot assay.  All studies are representative 
of at least three independent experiments in which n = 3. Mean shown as line. 
 
Figure 2.   Citrullinated vimentin-specific responses are CD4 mediated and produce 
granzyme B.  Splenocytes from mice immunized with citrullinated aa415-433 (A) or 
aa28-49 (B) peptides were subject to MHC class II blocking or CD4 depletion and 
peptide specific IFNγ responses assessed in Elispot assay.  C, Splenocytes from 
citrullinated peptide immunized mice were tested for peptide specific granzyme B 
release by Elisa.  All studies are representative of at least three independent 
experiments in which n = 3. Data are presented as mean + s.d. 
 
Figure 3.  Citrullinated peptides are presented on tumor cells in a PAD and 
autophagy-dependent manner.  Splenocytes from mice immunized with both 
citrullinated peptides were assessed for the ability to recognize tumor cells in IFNγ 
Elispot assay (A) or by granzyme B Elisa (B). Values are relative to tumor cell lines 
grown in complete medium. **P < 0.01, ****P < 0.0001. Representative of at least 
three independent experiments where n = 3.  C, (i) Western blot of B16DR4 tumor 
cell lysates probed for the LC3 autophagy marker with associated histogram 
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summarizing the densitometric analysis of the LC3-I and LC3-II bands normalized to 
β actin control and (ii) p62 Elisa showing induction of autophagy when treated with 
rapamycin, bafilomycin and serum starvation. Values are averaged with data from 
two independent experiments in which n = 3 and mean + s.d.  D, Recognition of 
nutrient-starved tumor cells and inhibition in the presence of autophagy and PAD 
inhibitors.  Representative of at least three independent experiments in which n = 3. 
Values are relative to B16DR4 cells grown in the presence or absence of serum as 
indicated. ***P < 0.001, ****P < 0.0001. Data are presented as mean + s.d. 
 
Figure 4.  Citrullinated vimentin peptide vaccination induces efficient tumor therapy.  
A,  Survival of mice challenged with B16DR4 tumor and immunized four days post 
tumor implant with citrullinated vimentin aa28-49, aa415-433 peptide or the 
combination.  B, Survival and tumor growth curves (C) of mice challenged with 
B16DR4 tumor and immunized 7, 10 or 14 days post tumor implant with citrullinated 
vimentin aa28-49 and aa415-433 peptides.  Studies are representative of at least 
two independent experiments in which n = 9.  D, Survival of mice challenged with 
high tumor load of B16DR4 cells (1.5 x 105) and immunized four days post tumor 
implant in combination with citrullinated vimentin aa28-49 and aa415-433 peptides. 
Study is representative of data from at least two independent studies in which n = 10. 
 
Figure 5.  Tumor therapy is CD4 mediated and IFNγ dependent.  Survival of mice 
challenged with B16DR4 tumor and immunized with citrullinated vimentin aa28-49 
and/or aa415-433 peptides at day 4 in presence of CD4-depleting antibody (A), CD8-
depleting antibody (B), IFNγ antibody (C) or IL-17 antibody (D).  All studies are 
representative of at least two independent experiments in which n = 10. 
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Figure 6.  Anti-tumor responses require expression of HLA-DR4 on the tumor.  A, 
Survival of mice challenged with B16F1 tumor cells knocked out for MHC class II 
were immunized four days post tumor implant in combination with citrullinated 
vimentin aa28-49 and aa415-433 peptides in which n = 10.  B, Normalized FACS 
profiles demonstrating expression of HLA-DR401 on the surface of B16F1 cells 
knocked out for murine MHC class II (i) transfected with the pDCGas HLA-DR401 
IFNγ inducible plasmid (ii) and with the constitutive high level expression pVitro 2 
HLA-DR401 plasmid (iii) on incubation without (Dark grey) and with (Black) IFNγ. 
Light grey profiles represent unstained samples.  C, Survival of mice challenged with 
the transfected B16F1 IFNγ inducible HLA-DR401 tumor cells and immunized four 
days post tumor implant in combination with citrullinated vimentin aa28-49 and 
aa415-433 peptides (n = 10).  D, Survival of mice challenged with LLC/2 HLA-DR401 
tumor and immunized four days post tumor implant with both citrullinated vimentin 
aa28-49 and aa415-433 peptides (n = 10) .  
 
Figure 7.  Are citrullinated proteins a novel class of tumor associated antigen?  A, 
C57Bl/6 mice were immunized with MOG 35-55 peptide citrullinated at position 46 
and analyzed for IFNγ responses by Elispot assay.  Representative of at least three 
independent experiments in which n = 3.  Data are presented as mean + s.d.  B, 
Survival of C57Bl/6 mice challenged with B16 tumor and vaccinated with MOG 35-55 
(cit46) peptide at days 4, 7 and 11 (n=10).  C, C57Bl/6 mice were immunized with 
citrullinated aa31-50 or aa401-419 peptides and analyzed for IFNγ responses by 
Elispot assay. D, Melanoma patient PBMCs were analyzed for proliferation to 
citrullinated aa28-49 or aa415-433 peptides by thymidine incorporation.  E, Normal 
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donor PBMCs were analyzed for proliferation to aa415-433 citrullinated peptide by 
thymidine incorporation and CFSE dilution.   
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